Edgewise Therapeutics EWTX
$39.91 −$1.27 (-3.07%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $39.91 0.00%
Open$40.81
Prev close$41.17
Day range$39.71 – $41.41
Volume1.19M
Market cap$4.37B
P/E (TTM)4.8
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$46.14M+1.5% YoY
Net profit$1.17B+2,967.6% YoY
Diluted EPS$9.65+2,574.4% YoY
Free cash flow-$78.31M-124.6% YoY
Operating cash flow-$78.29M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity92.1%
Return on assets85.4%
Return on invested capital90.1%
Current ratio12.30
Liabilities / assets8.3%
Cash & investments$1.74B
Total debt$2.36M
Net cash (debt)$1.74B
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $46.14M | $61.94M | $54.12M | $191.41M | $55.98M |
| Selling and Admin Expenses | $14.57M | $14.40M | $11.46M | $40.02M | $12.39M |
| -General & Admin Expense | $14.57M | $14.40M | $11.46M | $40.02M | $12.39M |
| Research & Development | $31.58M | $47.55M | $42.65M | $151.39M | $43.59M |
| Operating Profit | -$46.14M | -$61.94M | -$54.12M | -$191.41M | -$55.98M |
| Net Non-Operating Interest Income (Expense) | $16.50M | $4.62M | $5.10M | $23.61M | $5.76M |
| Non-Operating Interest Income | $16.50M | $4.62M | $5.10M | $23.61M | $5.76M |
| Other Income (Expense) | $1.35B | – | – | – | – |
| Special Income (Charges) | $1.35B | – | – | – | – |
| -Gain on Sale Of Business | $1.35B | – | – | – | – |
| Other Non-Operating Income (Expenses) | $3.07M | – | – | – | – |
| Pretax Profit | $1.32B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Tax | $155.33M | – | – | – | – |
| Net Profit | $1.17B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Profit from Continuing Operations | $1.17B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Net Income to Parent Company | $1.17B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Net Income to Common Stockholders | $1.17B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Basic EPS | $10.71 | -$0.53 | -$0.46 | -$1.63 | -$0.47 |
| Diluted EPS | $9.65 | -$0.53 | -$0.46 | -$1.63 | -$0.47 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.78B | $479.69M | $518.52M | $552.60M | $552.60M |
| Total Current Assets | $1.77B | $471.52M | $509.79M | $543.39M | $543.39M |
| Cash and Cash Equivalents & Short-Term Investments | $1.74B | $460.71M | $499.56M | $530.11M | $530.11M |
| -Cash and Cash Equivalents | $68.68M | $72.32M | $33.21M | $61.15M | $61.15M |
| -Short Term Investments | $1.68B | $388.39M | $466.35M | $468.96M | $468.96M |
| Other Current Assets | $28.58M | $6.45M | $10.23M | $13.28M | $13.28M |
| Total Non-Current Assets | $7.55M | $8.17M | $8.73M | $9.22M | $9.22M |
| Net PPE | $7.55M | $8.17M | $8.73M | $9.22M | $9.22M |
| -Gross PPE | $15.93M | $16.02M | $16.04M | $15.99M | $15.99M |
| -Accumulated Depreciation | -$8.38M | -$7.85M | -$7.31M | -$6.77M | -$6.77M |
| Total Liabilities | $147.35M | $31.61M | $25.32M | $30.35M | $30.35M |
| Total Current Liabilities | $144.11M | $29.04M | $22.54M | $27.37M | $27.37M |
| Payables | $118.54M | $4.67M | $7.29M | $6.01M | $6.01M |
| -Accounts Payable | $9.64M | $4.67M | $7.29M | $6.01M | $6.01M |
| -Total Tax Payable | $108.90M | – | – | – | – |
| Current Accrued Expenses | $10.56M | $5.19M | $8.56M | $7.92M | $7.92M |
| Short-Term Debt and Capital Lease Obligation | $1.03M | $1.02M | $1.02M | $1.01M | $1.01M |
| -Current Capital Lease Obligation | $1.03M | $1.02M | $1.02M | $1.01M | $1.01M |
| Current Deferred Liabilities | $5.18M | – | – | – | – |
| Total Non-Current Liabilities | $3.25M | $2.57M | $2.78M | $2.98M | $2.98M |
| Long Term Debt and Capital Lease Obligation | $2.36M | $2.57M | $2.78M | $2.98M | $2.98M |
| -Long Term Capital Lease Obligation | $2.36M | $2.57M | $2.78M | $2.98M | $2.98M |
| Other Non-Current Liabilities | $888,000.00 | – | – | – | – |
| Total Equity | $1.63B | $448.08M | $493.20M | $522.26M | $522.26M |
| Stockholders' Equity | $1.63B | $448.08M | $493.20M | $522.26M | $522.26M |
| Capital Stock | $10,000.00 | $10,000.00 | $10,000.00 | $10,000.00 | $10,000.00 |
| -Common Stock | $10,000.00 | $10,000.00 | $10,000.00 | $10,000.00 | $10,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.12B | $1.10B | $1.09B | $1.07B | $1.07B |
| Retained Earnings | $513.44M | -$652.71M | -$595.38M | -$546.37M | -$546.37M |
| Gains/Losses Not Affecting Retained Earnings | -$5.60M | -$500,000.00 | -$252,000.00 | $677,000.00 | $677,000.00 |
| Other Current Liabilities | – | $9.59M | – | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$78.29M | -$42.47M | -$42.54M | -$143.82M | -$38.59M |
| Net cash flow from continuing operations | -$78.29M | -$42.47M | -$42.54M | -$143.82M | -$38.59M |
| Net Income from Continuing Operations | $1.17B | -$57.33M | -$49.01M | -$167.80M | -$50.22M |
| Depreciation & Depletion & Amortization | $590,000.00 | $597,000.00 | $590,000.00 | $2.27M | $575,000.00 |
| Change in Working Capital | $97.20M | $5.71M | -$1.82M | -$5.37M | $2.66M |
| -Change in Prepaid Assets | -$19.32M | -$579,000.00 | $3.05M | -$7.96M | -$2.72M |
| -Change in Payables and Accrued Expense | $116.72M | $6.49M | -$4.67M | $3.34M | $5.57M |
| -Change in Other Current Liabilities | -$206,000.00 | -$203,000.00 | -$196,000.00 | -$748,000.00 | -$193,000.00 |
| Net cash flow from investing | $59.68M | $78.49M | $2.43M | -$32.79M | $49.76M |
| Net Cash Flow from Continuing Investing Activities | $59.68M | $78.49M | $2.43M | -$32.79M | $49.76M |
| Net PPE Purchase and Sale | -$17,000.00 | -$32,000.00 | -$260,000.00 | -$256,000.00 | -$73,000.00 |
| Net Investment Purchase and Sale | -$1.29B | $78.52M | $2.69M | -$32.53M | $49.84M |
| Financing Cash Flow | $14.98M | $3.09M | $12.17M | $196.09M | $3.98M |
| Net Cash Flow from Continuing Financing Activities | $14.98M | $3.09M | $12.17M | $196.09M | $3.98M |
| Net Common Stock Issuance | $0.00 | – | – | $187.36M | $0.00 |
| Proceeds from Stock Option Exercised | $14.98M | $3.09M | $12.17M | $8.73M | $3.98M |
| Ending Cash Balance | $68.68M | $72.32M | $33.21M | $61.15M | $61.15M |
| Net Change in Cash | -$3.64M | $39.11M | -$27.94M | $19.48M | $15.15M |
| Beginning Cash Balance | $72.32M | $33.21M | $61.15M | $41.67M | $46.00M |
| Free Cash Flow | -$78.31M | -$42.50M | -$42.80M | -$144.07M | -$38.67M |
No comments yet — be the first to weigh in on EWTX.
Sign in to join the discussion.